Publications in OpenAlex of which a co-author is affiliated to this organization
All publications | By field | By subfield
All publications [Next]
| Title | DOI |
|---|---|
| https://doi.org/10.2217/bmm.12.44 | Analytical Aspects of Molecular Alzheimer’s Disease Biomarkers |
| https://doi.org/10.1016/j.trci.2018.10.003 | Cerebrospinal fluid neurogranin/β‐site APP‐cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease |
| https://doi.org/10.1002/acn3.51553 | Phospho‐specific plasma p‐tau181 assay detects clinical as well as asymptomatic Alzheimer's disease |
| https://doi.org/10.1002/ana.26048 | Onset of Preclinical Alzheimer Disease in Monozygotic Twins |
| https://doi.org/10.1074/jbc.m114.627919 | Tau Monoclonal Antibody Generation Based on Humanized Yeast Models |
| https://doi.org/10.3233/jad-150953 | Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer’s Disease |
| https://doi.org/10.1186/s13195-017-0265-7 | Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1–42)/Aβ(1–40) |
| https://doi.org/10.3390/ijms22062931 | Plasma Amyloid-Beta Levels in a Pre-Symptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy Pedigree: A Cross-Sectional and Longitudinal Investigation |
| https://doi.org/10.1186/s13024-016-0130-3 | No diurnal variation of classical and candidate biomarkers of Alzheimer’s disease in CSF |
| https://doi.org/10.1002/alz.12228 | Plasma β‐secretase1 concentrations correlate with basal forebrain atrophy and neurodegeneration in cognitively healthy individuals at risk for AD |
| https://doi.org/10.1186/s13195-022-01038-z | P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profiles |
| https://doi.org/10.1038/s41514-023-00114-4 | Elevated plasma sclerostin is associated with high brain amyloid-β load in cognitively normal older adults |
| https://doi.org/10.1111/jnc.13527 | Validation of soluble amyloid‐β precursor protein assays as diagnostic |
| https://doi.org/10.3389/fneur.2022.890638 | Multi-Omics Interdisciplinary Research Integration to Accelerate Dementia Biomarker Development (MIRIADE) |
| https://doi.org/10.1186/s40364-022-00425-w | Bioinformatics tools and data resources for assay development of fluid protein biomarkers |
| https://doi.org/10.1016/j.cca.2019.07.024 | Pre-analytical stability of novel cerebrospinal fluid biomarkers |
| https://doi.org/10.1111/jnc.14680 | Cerebrospinal fluid levels of synaptic and neuronal integrity correlate with gray matter volume and amyloid load in the precuneus of cognitively intact older adults |
| https://doi.org/10.3389/fneur.2017.00310 | Multicenter Analytical Validation of Aβ40 Immunoassays |
| https://doi.org/10.1186/s13195-021-00899-0 | Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer’s disease, but not in cerebral amyloid angiopathy |
| https://doi.org/10.1186/s13195-024-01620-7 | Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer’s disease, positive for plasma p-tau217 |
| https://doi.org/10.1186/s13195-023-01201-0 | Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts |
| https://doi.org/10.1186/s13195-024-01409-8 | The use of synaptic biomarkers in cerebrospinal fluid to differentiate behavioral variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer’s disease |
| https://doi.org/10.1097/wnp.0000000000000767 | Optical Flow Estimation Improves Automated Seizure Detection in Neonatal EEG |
| https://doi.org/10.1038/s41591-022-02037-1 | Publisher Correction: Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease |
| https://doi.org/10.3171/2023.4.jns23347 | Preoperative white matter network organization and memory decline after epilepsy surgery |
| https://doi.org/10.1002/alz.083128 | Blood‐based SNAP‐25 and VAMP‐2 in Alzheimer’s disease; relation to cognition, atrophy and synaptic density. |
| https://doi.org/10.3389/fmolb.2020.00048 | A Novel Tau Antibody Detecting the First Amino-Terminal Insert Reveals Conformational Differences Among Tau Isoforms |
| https://doi.org/10.1093/braincomms/fcad024 | Plasma biomarkers predict amyloid pathology in cognitively normal monozygotic twins after 10 years |
| https://doi.org/10.1371/journal.pone.0153564 | A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid42 and DJ-1 in Human Cerebrospinal Fluid |
| https://doi.org/10.1002/alz.079647 | Preliminary performance of the Lumipulse G pTau 217 Plasma prototype assay on plasma samples |
| https://doi.org/10.1002/alz.082944 | Performance of optimized prototype LUMIPULSE G immunoassays for plasma pTau181 and pTau217 |
| https://doi.org/10.1002/alz.078393 | Plasma phosphorylated tau 217 levels are highly stable under common pre‐analytical sample handling procedures |
| https://doi.org/10.1002/alz.083029 | The detection of phosphorylated tau in tear fluid |
| https://doi.org/10.1002/alz.082999 | Performance testing of a novel GFAP ELISA for CSF and blood based matrices |
| https://doi.org/10.1002/alz.046703 | Cerebrospinal fluid biomarker levels are not affected by aspiration or gravity drip extraction methods in Alzheimer’s disease: The AIBL study |
| https://doi.org/10.1002/alz.064341 | Plasma pTau181/Aβ42 identifies cognitive change earlier than CSF pTau181/Ab42 |
| https://doi.org/10.1046/j.1528-1157.2003.36202.x | Neocortical Temporal FDG‐PET Hypometabolism Correlates with Temporal Lobe Atrophy in Hippocampal Sclerosis Associated with Microscopic Cortical Dysplasia |
| https://doi.org/10.1159/000218200 | Conservative Management of Acute Epidural Hematoma in a Pediatric Age Group |
| https://doi.org/10.1186/s13195-016-0209-7 | Prospective longitudinal course of cognition in older subjects with mild parkinsonian signs |
| https://doi.org/10.1159/000230710 | In vitro Sonothrombolysis with Duplex Ultrasound: First Results Using a Simplified Model |
| https://doi.org/10.1002/acn3.50948 | APP‐derived peptides reflect neurodegeneration in frontotemporal dementia |
| https://doi.org/10.1097/qai.0000000000002596 | Social Isolation Is Linked to Inflammation in Aging People With HIV and Uninfected Individuals |
| https://doi.org/10.1002/alz.038179 | Amyloid, pTau, NfL, and GFAP as biomarkers for Alzheimer’s disease |
| https://doi.org/10.3233/jpd-223285 | Comparative Analysis of Total Alpha-Synuclein (αSYN) Immunoassays Reveals That They Do Not Capture the Diversity of Modified αSYN Proteoforms |
| https://doi.org/10.1016/j.jpsychires.2022.10.010 | Glutamate receptor 4 as a fluid biomarker for the diagnosis of psychiatric disorders |
| https://doi.org/10.1002/alz.076863 | Plasma SNAP‐25 as a potential Alzheimer’s disease biomarker |
| https://doi.org/10.1002/mds.29336 | |
| https://doi.org/10.1159/000017406 | Focal Cortical Dysplasia in Children |
| https://doi.org/10.1097/gim.0b013e31818337a8 | Genome-wide gene expression profiling and mutation analysis of Saudi patients with Canavan disease |
| https://doi.org/10.3233/jad-150511 | Transferring Cut-off Values between Assays for Cerebrospinal Fluid Alzheimer’s Disease Biomarkers |
| https://doi.org/10.3934/molsci.2015.2.144 | The peptidyl prolyl cis/trans isomerase Pin1/Ess1 inhibits phosphorylation and toxicity of tau in a yeast model for Alzheimer’s disease |
| https://doi.org/10.1177/2472630317750378 | Automation on an Open-Access Platform of Alzheimer’s Disease Biomarker Immunoassays |
| https://doi.org/10.4103/0972-5229.123463 | Refractory hyperkalemia related to heparin abuse |
| https://doi.org/10.1002/alz.045763 | A biorepository for the in‐depth validation of pre‐analytical sample handling effects on novel blood‐based biomarkers for Alzheimer’s disease: The first results |
| https://doi.org/10.1016/j.jalz.2015.06.956 | P3‐089: Measurement of ß‐amyloid isoforms (1‐38, 1‐40, 1‐42) in plasma by new sensitive and accurate elisas |
| https://doi.org/10.1159/000017403 | Hippocampal Chemical Anatomy in Pediatric and Adolescent Patients with Hippocampal or Extrahippocampal Epilepsy |
| https://doi.org/10.1016/j.neurobiolaging.2019.12.017 | Association of brain network dynamics with plasma biomarkers in subjective memory complainers |
| https://doi.org/10.1515/cclm-2020-1521 | Cerebrospinal fluid hemoglobin levels as markers of blood contamination: relevance for α-synuclein measurement |
| https://doi.org/10.1186/alzrt253 | Roadblocks for integration of novel biomarker concepts into clinical routine: the peptoid approach |
| https://doi.org/10.1016/j.jalz.2017.07.061 | [O1–05–04]: CLINICAL PERFORMANCE OF NEUROGRANIN AS A CEREBROSPINAL FLUID BIOMARKER FOR ALZHEIMER's DISEASE: AN ASSAY COMPARISON STUDY |
| https://doi.org/10.1016/j.jalz.2018.06.2824 | O3‐09‐06: A PROTOTYPE SIMOA ASSAY QUANTIFYING PLASMA AMYLOID BETA 1‐42 AND 1‐40 ISOFORMS CAN DIFFERENTIATE PARTICIPANTS WITH AD FROM HEALTHY CONTROL SUBJECTS |
| https://doi.org/10.1002/alz.052959 | Distinctive effect of biological sex in AD‐related CSF and plasma biomarkers |
| https://doi.org/10.1002/alz.057860 | Plasma p‐Tau181 and p‐Tau231 offer complementary information to identify Alzheimer's disease pathophysiology |
| https://doi.org/10.1002/alz.065391 | A head‐to‐head comparison of plasma phosphorylated tau assays in the real‐world memory clinic |
| https://doi.org/10.1016/j.jalz.2015.07.410 | O4‐11‐06: The confidence level of established cut‐off values for CSF Alzheimer's disease‐specific biomarkers |
| https://doi.org/10.1159/000336265 | Bent Spine Syndrome: A Phenotype of Dysferlinopathy or a Symptomatic DYSF Gene Mutation Carrier |
| https://doi.org/10.1016/j.jalz.2015.06.609 | P2‐072: Development of novel elisas for the quantification of both pan‐ApoE and ApoE4 proteins in CSF and blood, and ApoE ε4 phenotyping |
| https://doi.org/10.1002/alz.043506 | Development of an ultrasensitive multiplex assay for simultaneous detection of Aβ1‐42, Aβ1‐40, GFAP and NF‐L in blood |
| https://doi.org/10.1186/s13195-021-00812-9 | Core Alzheimer’s disease cerebrospinal fluid biomarker assays are not affected by aspiration or gravity drip extraction methods |
| https://doi.org/10.1016/j.jalz.2019.06.4443 | F2‐07‐04: PLASMA AMYLOID BETA 1–42 AND 1–40 MEASURED BY A NOVEL SIMOA ASSAY AS A DIAGNOSTIC TOOL FOR ALZHEIMER'S DISEASE PATHOLOGY |
| https://doi.org/10.1002/alz.045110 | Comparison of two analytical platforms for blood‐based surrogate biomarkers of amyloid pathology |
| https://doi.org/10.1002/alz.054911 | Development and analytical characterization of novel tau Simoa assays targeting full‐length tau in CSF and mid‐tau in CSF and plasma |
| https://doi.org/10.1002/alz.068847 | Plasma biomarkers associations with cognitive change in preclinical Alzheimer’s disease |
| https://doi.org/10.1002/alz.068159 | The effects of age and sex on plasma p‐tau181 concentrations in Alzheimer’s Disease |
| https://doi.org/10.1016/j.neurobiolaging.2024.06.001 | Cerebrospinal fluid biomarkers and cognitive trajectories in patients with Alzheimer’s disease and a history of traumatic brain injury |
| https://doi.org/10.1186/s13195-024-01518-4 | Correction: Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid angiopathy |
| https://doi.org/10.1159/000120385 | Neonatal Cerebral Venous Thrombosis |
| https://doi.org/10.1046/j.1365-2230.1999.00415.x | Dermatomyositis in association with transitional cell carcinoma of the bladder |
| https://doi.org/10.1016/j.jalz.2013.04.185 | O2–09–03: Detection and quantification of novel tau/phospho‐tau epitopes in CSF using a multiplex assay approach |
| https://doi.org/10.1016/j.jalz.2014.05.395 | P1‐157: AUTOMATION OF AMYLOID ELISAS BRINGS ALZHEIMER'S BIOMARKER STANDARDISATION ONE STEP FURTHER |
| https://doi.org/10.1002/alz.053858 | Amyloid‐βeta peptides in CSF and plasma discriminate cerebral amyloid angiopathy from controls |
| https://doi.org/10.1016/j.neurobiolaging.2014.01.117 | Tau as a molecular biomarker in cerebrospinal fluid and plasma |
| https://doi.org/10.1016/j.jalz.2016.06.1330 | P2‐163: Performance Evaluation of New Absorbance‐Based Elisas for Measuring Different Alpha‐Synuclein (A‐SYN) Species in CSF and Plasma |
| https://doi.org/10.1016/j.jalz.2017.06.2018 | [P4–151]: ALPHA‐SYNUCLEIN BIOMARKER ANALYSIS: ANALYTICAL PERFORMANCE AND INTER‐LABORATORY PRECISION USING A NEW COLORIMETRIC ELISA |
| https://doi.org/10.1016/j.jalz.2017.06.2019 | [P4–152]: DIFFERENCES IN ANALYTICAL SELECTIVITY OF β‐AMYLOID (1–42) IMMUNOASSAYS EXPLAIN DISCORDANT RESULTS IN STUDY COMPARISONS |
| https://doi.org/10.1016/j.jalz.2017.06.1461 | [P3–248]: PLASMA AMYLOID BETA LEVELS, CEREBRAL SMALL‐VESSEL DISEASES AND COGNITION: THE ROTTERDAM STUDY |
| https://doi.org/10.1016/j.jalz.2018.06.1605 | P3‐246: C‐REACTIVE PROTEIN, PLASMA AMYLOID BETA LEVELS AND MRI MARKERS: THE ROTTERDAM STUDY |
| https://doi.org/10.1016/j.jalz.2019.06.4859 | O5‐05‐02: CSF BIOMARKERS OF SYNAPTIC DAMAGE (NEUROGRANIN, SNAP25) AND INTERNEURON‐DEPENDENT SYNAPTIC HOMEOSTASIS (NPTX2) IMPROVE DIAGNOSTIC CLASSIFICATION OF MCI AND AD AND CORRELATE WITH COGNITION |
| https://doi.org/10.1016/j.jalz.2019.06.4556 | O1‐07‐04: CSF BIOMARKERS OF AMYLOID, TAU AND SYNAPTIC DAMAGE (NEUROGRANIN, SNAP25) AND INTERNEURON‐DEPENDENT SYNAPTIC HOMEOSTASIS (NPTX2) IN CSF AS PREDICTORS OF COGNITIVE PROGRESSION IN MCI AND AD |
| https://doi.org/10.1002/alz.051338 | A panel of novel astrocytic and synaptic biomarkers in serum and CSF for the differential diagnosis of frontotemporal dementia |
| https://doi.org/10.1002/alz.055316 | Comparing the clinical utility and diagnostic performance of cerebrospinal fluid P‐tau181, P‐tau217 and P‐tau231 assays |
| https://doi.org/10.1002/alz.067140 | Diagnostic value of serum versus plasma phospho‐tau for Alzheimer’s disease |
| https://doi.org/10.1002/ana.26675 | Correction: Decreased Cerebrospinal Fluid Amyloid β 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid Angiopathy |
| https://doi.org/10.1002/alz.079533 | Performance of plasma pTau181 and pTau217 measured with fully automated LUMIPULSE G prototype immunoassays |
| https://doi.org/10.1016/j.jalz.2015.08.061 | P4‐232: A monoclonal antibody‐based elisa for neurogranin |
| https://doi.org/10.1002/alz.041849 | Cerebrospinal fluid tau biomarkers in the prediction and concordance of neurofibrillary tangle and amyloid pathology |
| https://doi.org/10.1101/2023.07.11.23292493 | Diagnostic accuracy of the plasma ALZpath pTau217 immunoassay to identify Alzheimer’s disease pathology |
| https://doi.org/10.1101/lm.178406 | Lack of evidence for a role of medial temporal lobe structures in visual perception |
| https://doi.org/10.1101/2024.08.22.24312244 | The Alzheimers Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau Round Robin study |
| https://doi.org/10.21203/rs.3.rs-155736/v1 | Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer’s disease |